Fig 1: Sex influences CD79b-positive immune cells in bladders of developmentally exposed mice. Mice were exposed to PCBs via maternal diet through gestation and lactation. Bladders were collected from young male and female offspring at postnatal day (P) 28–31 for immunohistochemistry. Representative images of (A) male and (B) female mouse bladders at each PCB treatment group incubated with antibodies targeting CD79b (brown) to label immune cells and hematoxylin (purple) to label all nuclei. Quantification of (C) total cells CD79b positive within bladder, (D) epithelial cells CD79b positive within bladder, and (E) stromal cells CD79b positive within the bladder. Results are the mean ± SEM, n = 4–6 bladders per treatment group. * indicates significant differences at p < 0.05, as determined using two-way ANOVA.
Fig 2: Validates the role of the key gene CD79B in lung cancer cell lines in vitro. (A) Knockdown of CD79B significantly reduced its expression in A549 and h1299 cell lines (**P<0.01, **P<0.001). (B) After CD79B knockdown in A549 and H1299 cell lines, the activity of lung adenocarcinoma cells was significantly enhanced (**P<0.01, *** (P<0.001). (C) Clonogenic assays showed a significant increase in the ability of A549 and H1299 cell lines to form colonies after CD79B knockdown (**P<0.01). (D) The si-NC group in the wound healing experiment of A549 and H1299 cell lines showed weaker migration ability than the si-CD79B group (*P<0.05, **P<0.01). (E) Knockdown of CD79B enhanced the invasion ability of A549 and H1299 cell lines (**P<0.01, *** (P<0.001).
Fig 3: CD79a and CD79b CAR T cells are functional in vitro and in vivo. (A) Schematic of CD19, CD79a, or CD79b CAR constructs. (B) Lysis of indicated tumor cell lines by chromium release assay. Data are means ± SEM from 3 independent experiments. (C) CAR T-cell IL-2 or IFN-γ production measured by ELISA. Data are means ± SEM from 4 independent experiments. P values were calculated with one-way ANOVA with post hoc Tukey multiple comparisons test. (D-E) NSG mice were inoculated with JeKo-1 ffluc tumor cells and either left untreated or treated at day 7 with a total of 2 × 106 of CD79a, CD79b, or CD19 CAR T cells (CD4:CD8 at 1:1 ratio). (D) Bioluminescent imaging of tumor bearing mice at indicated time points. Each line represents measurements of a single mouse in each of the treatment groups. (E) Survival of mice from 2 independent experiments, each containing 5 to 8 mice per group. (F) Representative flow cytometric analysis of T cells and tumor cells in BM suspensions from JeKo-1 tumor bearing mice treated with CD79a, CD79b, or CD19 CAR T cells on the day that mice met criteria for euthanasia. Top panels were gated on singlets, live cells, and CD45+CD8+ (blue) or CD45+CD4+ (red) population. CAR staining was measured by CD79ab-Fc or anti-STII antibody binding. Bottom panels were gated on singlets, live cells, and CD45+GFP+ Jeko-1 ffluc cells. ANOVA, analysis of variance; ELISA, enzyme-linked immunosorbent assay; SEM, standard error of the mean; TM, transmembrane domain.
Fig 4: Design and in vitro characterization of bispecific CARs. (A) Schematics of bispecific CAR T-cell formats. (B) Top panels: lysis of the indicated tumor cell lines by CD19, CD79a, and bispecific CD79a-CD19 CAR T cells. tCD79a-CD19 refers to tandem CAR; bCD19-CD79a refers to bicistronic CAR. Bottom panel: lysis of the indicated tumor cell lines by CD19, CD79b, and bispecific CD79b-CD19 CAR T cells. tCD79b-CD19 refers to tandem CAR; bCD19-CD7b refers to bicistronic CAR. (C) CAR T-cell IL-2 and IFN-γ production measured by ELISA. Data given in (A-B) are means ± SEM from 3 independent experiments. ELISA, enzyme-linked immunosorbent assay; SEM, standard error of the mean.
Fig 5: CD79ab is expressed on lymphoma cell lines and primary tumor specimens. (A) CD19 and CD79b density on each indicated tumor cell line measured via ABC. (B) Expression of CD19, CD79a, and CD79b measured by IHC on primary lymphoma specimens. ABC, antibody-binding capacity; Burkitt’s, Burkitt’s lymphoma; FL, follicular lymphoma; MALT, lymphoma of the mucosa-associated lymphoid tissue.
Supplier Page from Abcam for Anti-CD79b antibody [EPR6861]